Orbimed Advisors, a fund focused on the healthcare sector, led by Samuel Isaly
, disclosed minutes ago purchasing 125,000 shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX
). The fund purchased the shares in one transaction, at a price of $17.50 apiece, increasing its position to a total of 1.3 million shares.
Through the acquisition, Orbimed follows Baker Bros., which recently disclosed buying 400,000 shares of Mirati
Mario Gabelli Takes +5% Stakes in Global Sources Ltd and Belo Corp
Howard Marks Discloses 6.8% of Contango Oil & Gas, Affiliates Close Out of Crimson Exploration
4 Hedge Funds Heavily Invested in Apple’s Fate